thalidomide has been researched along with Hyperthyroidism in 2 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Hyperthyroidism: Hypersecretion of THYROID HORMONES from the THYROID GLAND. Elevated levels of thyroid hormones increase BASAL METABOLIC RATE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide has been proven to be helpful and averted the adverse effects from systemic corticosteroids and other immunosuppressive drugs in this patient." | 5.38 | Propylthiouracil-induced ANCA-positive erythema nodosum treated with thalidomide. ( Hunasehally, RY; Shi, R; Wan, P; Zhao, X; Zheng, J, 2012) |
| "Primary hypothyroidism is the most common side effect, although thyrotoxicosis and effects on thyroid-stimulating hormone secretion and thyroid hormone metabolism have also been described." | 2.47 | Thyroid dysfunction from antineoplastic agents. ( Hamnvik, OP; Larsen, PR; Marqusee, E, 2011) |
| "Thalidomide has been proven to be helpful and averted the adverse effects from systemic corticosteroids and other immunosuppressive drugs in this patient." | 1.38 | Propylthiouracil-induced ANCA-positive erythema nodosum treated with thalidomide. ( Hunasehally, RY; Shi, R; Wan, P; Zhao, X; Zheng, J, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hamnvik, OP | 1 |
| Larsen, PR | 1 |
| Marqusee, E | 1 |
| Wan, P | 1 |
| Zhao, X | 1 |
| Hunasehally, RY | 1 |
| Shi, R | 1 |
| Zheng, J | 1 |
1 review available for thalidomide and Hyperthyroidism
| Article | Year |
|---|---|
Thyroid dysfunction from antineoplastic agents.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antica | 2011 |
1 other study available for thalidomide and Hyperthyroidism
| Article | Year |
|---|---|
Propylthiouracil-induced ANCA-positive erythema nodosum treated with thalidomide.
Topics: Antibodies, Antineutrophil Cytoplasmic; Antithyroid Agents; Erythema Nodosum; Female; Humans; Hypert | 2012 |